Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 - MAS, Adult onset Still's Disease, Chronic Obstructive Pulmonary Disease and many others.
AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze